Combination treatment for chronic lymphocytic leukemia that has returned
This trial tests two drugs, pirtobrutinib and epcoritamab, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after at least one previous treatment. The goal is to see if this combination can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CLL or SLL that has returned or did not respond to at least one previous treatment.
- You are 18 years or older.
- You are generally able to care for yourself (ECOG performance status 0-2).
- Your blood counts are within certain limits (hemoglobin >8 g/dL, neutrophils >1,000/μL, platelets >30,000/μL).
- Your kidney and liver function are adequate (based on blood tests).
- You have not had certain prior treatments, such as CAR-T therapy, bispecific antibodies, or pirtobrutinib in the last 24 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug epcoritamab as a consolidation therapy for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have had a partial response to a second-generation BTK inhibitor (with or without obinutuzumab) but still have detectable disease. The goal is to see if adding this treatment can lead to a deeper response and better outcomes.
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
This trial tests a new combination of an oral targeted therapy and a short course of chemotherapy for patients with previously untreated chronic lymphocytic leukemia (CLL). The goal is to control the disease and improve outcomes.
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
This trial tests a combination of two drugs, pirtobrutinib (a pill) and obinutuzumab (an infusion), given for a set period of time in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had any previous treatment for their disease. The goal is to see if this combination can control the cancer effectively.
This trial tests two oral targeted drugs—pirtobrutinib and venetoclax—for people with CLL or SLL whose disease has continued to grow despite taking a BTK inhibitor (such as ibrutinib, acalabrutinib, or zanubrutinib). The goal is to see if this combination can control the cancer when a BTK inhibitor alone is no longer working.
Hear when a new CLL/SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.